Email ID
Password
Scrip   
AstraZeneca files Brilinta in the US
19 November 2009
Asher Mullard

AstraZeneca has filed its antiplatelet therapy Brilinta (ticagrelor) with the US FDA for the reduction of major adverse cardiac events in patients with acute coronary syndromes (ACS). The submission comes just days after it presented further promising subgroup results of the drug's efficacy...



Please Login to read the full article.
JOB OF THE WEEK Promote your vacancy here
© 2010 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36